ArticleThe New England journal of medicine2022
Molnupiravir - A Step toward Orally Bioavailable Therapies for Covid-19.
Article in The New England journal of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rapid review and meta-analysis of adverse events associated with molnupiravir in patients with COVID-19.British journal of clinical pharmacology · 2022Pooled it
- Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case-Control Study (SAVALO Study).Microorganisms · 2025Article
- Risk factors for the mortality of hemodialysis patients with COVID-19 in northern Hunan province, China.BMC nephrology · 2025Article
- Nationwide Target Trial Emulation Evaluating the Clinical Effectiveness of Oral Antivirals for COVID-19 in Korea.Journal of Korean medical science · 2024Article
- BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir.Antimicrobial agents and chemotherapy · 2024Article
- Article
- Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics.Molecular aspects of medicine · 2023Review
- OligoBinders: Bioengineered Soluble Amyloid-like Nanoparticles to Bind and Neutralize SARS-CoV-2.ACS applied materials & interfaces · 2023Article
- Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants.Metabolites · 2023Review
- Evaluation of an automated CRISPR-based diagnostic tool for rapid detection of COVID-19.Heliyon · 2023Article
- The development of COVID-19 treatment.Frontiers in immunology · 2023Review
- Sotrovimab Lowers the Risk of COVID-19 Related Hospitalization or Death in a Large Population Cohort in the United Arab Emirates.Clinical pharmacology and therapeutics · 2022Article
- Deuterated Drugs and Biomarkers in the COVID-19 Pandemic.ACS omega · 2022Review
- Article
- In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment.Vaccines · 2022Article
- In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment.bioRxiv : the preprint server for biology · 2022Article
- Optimization of 2-Aminoquinazolin-4-(3Pharmaceuticals (Basel, Switzerland) · 2022Article
- Comparative evaluation of authorized drugs for treating Covid-19 patients.Health science reports · 2022Article
- Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US.PharmacoEconomics · 2022Article
- Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.Journal of molecular modeling · 2022Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.